BDRX

Biodexa Pharmaceuticals plc Sponsored ADR · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website biodexapharma.com
Employees(FY) 27
ISIN US59564R8079

Performance

-9.93%

+11.14%

-56.39%

-83.75%

-94.04%

YTD

-93.86%

Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing products aimed at primary and metastatic cancers of the brain in the United Kingdom. The company is developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. In addition, the company offers licensing for MTD 201 (Q-octreotide) and MTD211 (Q-brexpiprazole). The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Advanced Technical Analysis

Technical Analysis of BDRX 2024-12-20

The stock indicators reflect a bearish sentiment, with the Moving Average Score at 10, Oscillators Score at 36, and a Technical Score of 23, indicating overall weakness in price momentum and suggesting caution for potential investors. The low scores across all categories highlight a lack of bullish signals in the current market environment.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of BDRX

Stock Rank

Recent News & Updates

2024-11-21 19:30
Result of General Meeting(Globenewswire)
2024-11-20 18:35
Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic(Accesswire)
2024-11-11 19:48
Biodexa Pharmaceuticals PLC ( Biodexa or the Company ) Regains Compliance For Continued Listing on Nasdaq(Globenewswire)
2024-11-07 03:30
Notice of General Meeting(Globenewswire)
2024-10-16 19:30
Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer(Accesswire)
2024-10-15 04:15
Biodexa Announces Successful Appeal of Nasdaq Delisting(Globenewswire)
2024-10-03 20:30
Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma(Globenewswire)
2024-09-25 20:30
Interim results for the six months ended June 30, 2024(Globenewswire)
2024-09-19 04:30
ADR Ratio Change(Globenewswire)
2024-09-15 20:30
Announces Payment of $3.0MM Final Match Payment Enabling Access to Remainder of $17.0MM CPRIT Grant(Globenewswire)
2024-08-30 04:30
Receipt of Nasdaq Delisting Determination - Plans to Appeal(Globenewswire)
2024-07-22 20:30
Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement(Globenewswire)
2024-07-18 20:30
Announces Pricing of $5.0 Million Registered Direct Offering and Concurrent Private Placement(Globenewswire)
2024-07-15 20:30
Biodexa Announces Phase 2a Study of Tolimidone in Type 1 Diabetes Approved by Health Canada(Globenewswire)
2024-07-11 19:41
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday(Investorplace)
2024-07-11 00:51
JOBY Stock Pops After Completing 523-Mile eVTOL Flight(Investorplace)
2024-07-11 00:31
KZIA Stock Alert: Kazia Continues Its Surge on Thursday With 51% Gains(Investorplace)
2024-07-11 00:10
Why Is Biodexa Pharmaceuticals (BDRX) Up 56% Today?(Investorplace)
2024-07-10 20:30
Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa in Treatment Of Precancerous Polyps in the GI Tract - Now 12-Month Data(Accesswire)
2024-07-01 20:30
Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024(Globenewswire)
2024-06-23 20:30
Biodexa Announces Positive Phase 2 Clinical Trial Results of eRapa at 12 months in Familial Adenomatous Polyposis (FAP)(Globenewswire)
2024-06-12 21:35
Results of Annual General Meeting(Globenewswire)
2024-06-09 20:30
Twelve month Phase 2 Clinical Trial Results of eRapa in Familial Adenomatous Polyposis (FAP) to be Presented at Prestigious Biennial InSIGHT 2024 Meeting in Barcelona(Globenewswire)
2024-06-02 20:00
Promising Phase 2 Results For Biodexa's eRapa(TM) Indicates Hope for FAP Patients Who Otherwise Have a 100% Lifetime Risk of Colorectal Cancer(Accesswire)
2024-05-21 20:30
Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises(Globenewswire)
2024-05-20 20:30
Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa's Newly-licensed eRapa in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting(Globenewswire)
2024-05-20 20:28
Why Is Biodexa Pharmaceuticals (BDRX) Stock Up 78% Today?(Investorplace)
2024-05-20 19:39
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday(Investorplace)
2024-05-14 15:58
Posting of Annual Report & Notice of AGM - Total Voting Rights(Globenewswire)
2024-05-08 20:00
Biodexa Looks To Prevent Or Delay The Worst Outcomes For Adolescents And Young Adults With Devastating Precancerous Condition(Accesswire)

Page 1 of 3

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.